ClinicalTrials.gg
CompletedNCT02910232Updated Sep 22, 2016

In Vivo Clinical Trial of Porous Starch - Hydroxyapatite Composite Biomaterials for Bone Regeneration

An observational study in Open Fracture of Foot, sponsored by Chiang Mai University. Completed at 1 site in Thailand. Open to participants aged 20 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-09-22.

Sponsored by Chiang Mai University · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
44
Ages
20 Years to 60 Years
Sex
All
01

Study summary

Biodegradable scaffold is an accepted and commercialized medical alternative choice for bone regeneration. In this project we will used our new invention, porous starch- hydroxyapatite composite, for in vivo clinical trial.

Read the detailed description

The products were prepared from medical grade Thai rice starch mixed with high purity (>97%) hydroxyapatite powder from fresh cow bone, and already passed in vivo animal biocompatility test, then processed by freeze-drying. There were 44 volunteers from orthopedic and neurosurgical division, 4 and 40 patients, respectively.

02

Conditions studied

  • Open Fracture of Foot

Browse trials for

Keywords

  • Rice starch
  • Porous composite
  • Biomaterial
  • Bone regeneration
  • Clinical trial
  • Hydroxyapatite
03

In context

Fractures, Open

53 studies on the registry are indexed under Fractures, Open; 14 are open to participants now.

This study's enrollment of 44 is below the median of 93 across 13 observational studies indexed under Fractures, Open.

Browse Fractures, Open studies →

Lead sponsor

Chiang Mai University is the lead sponsor of 119 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

There were 44 volunteers from orthopedic and neurosurgical division.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A patient who requires treatment by surgery and product implant in bone.
  • Not indicate sex type
  • 18-65 years
  • Patients accepted participate in the study.
  • Type of surgery will be treat for only bone.

Exclusion criteria

Exclusion Criteria:

  • Refused to join the study.
  • Patients have an allergic history of carbohydrates and bovine bone.
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
44 participants (actual)
Patient registry
No

Groups and cohorts

  • 1

    The groups were orthopedic patients and neurosurgical patients. The samples to fill the voiding space of bone and skull same as autografts.

    Device: bone void filler

Interventions

  • Devicebone void filler

    Bone void filler device prepared from porous starch-hydroxyapatite composites for bone regeneration

06

What researchers measure

Primary outcomes

  1. Bone voids repairing

    The primary outcome will be assessed from satisfactory grading by operative nurses and surgeons. Add a convenient storage, package removal, contamination risk, unused material disposal, size appropriateness, tolerability by hand, ease to cut, stability when wet, weight, and disturbance to operative field.

    Time frame: 6 months

Secondary outcomes

  1. Bone voids repairing

    The short and long term safety and efficacy were assessed during real time operation, such as material dislodgement. Add a during follow up time for at least 1 months such as infection and allergic reaction by X-ray follow up assessment at 1, 3 and 6 months intervals, after operations.

    Time frame: 6 months

07

Study locations

1 site
  • Biomedical Materials and Ceramic Industrial Research Unit
    Chiang Mai, 50200, Thailand
08

References and documents

Publications

  • Holzapfel BM, Reichert JC, Schantz JT, Gbureck U, Rackwitz L, Noth U, Jakob F, Rudert M, Groll J, Hutmacher DW. How smart do biomaterials need to be? A translational science and clinical point of view. Adv Drug Deliv Rev. 2013 Apr;65(4):581-603. doi: 10.1016/j.addr.2012.07.009. Epub 2012 Jul 20. PubMed 22820527 ↗
  • Dimitriou R, Jones E, McGonagle D, Giannoudis PV. Bone regeneration: current concepts and future directions. BMC Med. 2011 May 31;9:66. doi: 10.1186/1741-7015-9-66. PubMed 21627784 ↗
  • Mendes SC, Reis RL, Bovell YP, Cunha AM, van Blitterswijk CA, de Bruijn JD. Biocompatibility testing of novel starch-based materials with potential application in orthopaedic surgery: a preliminary study. Biomaterials. 2001 Jul;22(14):2057-64. doi: 10.1016/s0142-9612(00)00395-1. PubMed 11426886 ↗

Individual participant data

Plan to share: Yes — yes, we plan

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2014, a primary completion of Nov 2015 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2016
First posted
Sep 22, 2016
Start
Feb 2014
Primary completionActual
Nov 2015
CompletionActual
Jan 2016
Last update
Sep 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02910232
Responsible party
Sittiporn Punyanitya (Principal Investigator, Chiang Mai University) — Principal investigator
First posted
Sep 22, 2016
Start date
Feb 2014
Primary completion
Nov 2015
Completion
Jan 2016
Last update
Sep 22, 2016

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion